NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 19, 2014 at 2:45 AM

NeuroVive consolidates positioning as leading mitochondrial medicine company Twelve months (1 Jan. 2013 – 31 Dec. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 1,598,000 (1,328,000). · Loss before tax was SEK -22,126,000 (-15,903,000). · Earnings per share* were SEK -1.17 (-0.85). · Diluted earnings per share** were SEK -1.17 (-0.85). Fourth quarter (1 Oct. 2013 – 31 Dec. 2013) · Net revenues were SEK 0 (0) and other operating income was SEK 12 (808,000). · Loss before tax was SEK -9,169,000 (-5,148,000). · Earnings per share* were SEK -0.45 (-0.25). · Diluted earnings per share** were SEK-0.45 (-0.25). * Profit/loss for the period divided by the average number of shares before dilution at the end of the period. **Profit/loss for the period divided by the average number of shares after dilution at the end of the period. Business highlights 2013 First Quarter · In March, NeuroVive acquired a portfolio of new cyclophilin inhibitors and the associated intellectual property from UK biotech enterprise Biotica Ltd. · On 22 March, NeuroVive reported that over 600 patients had been enrolled in the clinical phase III multi-center trial (CIRCUS), which is evaluating the effects of CicloMulsion® on treating reperfusion injury after stenting coincident with myocardial infarction. Second Quarter · 10th of April, NeuroVive had its IPO on NASDAQ OMX Small Cap, with stock symbol NVP. · Patient 700 of totally 972 has been enrolled to its multinational phase III trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) or treating reperfusion injury in myocardial infarction. · First patient has been enrolled to a clinical phase IIa trial on the company’s pharmaceutical NeuroSTAT® for treating traumatic brain damage. This trial covers a total of 20 patients and is being conducted at the neurology clinic of the Danish National Hospital in Copenhagen. · In June, NeuroVive signed a collaboration agreement with Isomerase Therapeutics to develop the molecules the company acquired from Biotica Ltd. in March 2013. The focus of this partnership is cell protection in traumatic brain damage, heart attack and in the new product segment of anti-viral indications in the form of a new product designated NVP018/BC556. · NeuroVive’s subsidiary NeuroVive Pharmaceutical Asia Ltd. received SEK 5.3 m(RMB 5 m) as a first milestone payment from NeuroVive’s collaboration partner in China, Sihuan Pharmaceutical. Third Quarter · Over 800 of the 972 patients have been enrolled in the multinational phase III trial on the company’s pharmaceutical CicloMulsion® (CIRCUS trial) to treat reperfusion injury coincident with myocardial infarction. · With its collaboration partner Sihuan, NeuroVive participated in the 18th Army Neurosurgery Annual Conference in Beijing, China. Fourth Quarter · Over 900 of the 972 patients have been enrolled in the multinational phase III trial on the company’s pharmaceuticals CicloMulsion® (CIRCUS trial) to treat reperfusion injury coincident with myocardial infarction. · Catharina Jz Johansson appointed as new CFO and takes up position on 1 December 2013. · EGM resolves on private placement and rights issue totaling approximately SEK 111 m, plus a SEK 10 m overallocation option. · NeuroVive completes a SEK 35 m private placement in December. Post balance sheet events · Extended partnership agreement with InVentiv Health to prepare for upcoming market launch CicloMulsion® · On 31 January, NeuroVive announces its rights issue is 270% oversubscribed. The Board of Directors announces its decision to fully exercise its overallocation option at the same time. The rights issue raises approximately SEK 75.8 m for NeuroVive and the overallocation option adds a further SEK 10.0 m. This means that NeuroVive raises a total of approximately SEK 85.8 m before issue expenses. · NeuroVive treats final patient in European phase III trial on CicloMulsion® Read the Year-End Report attached below NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this news release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 08:30 CEST on 19 January 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

McKay Brothers Enhances Fastest Routes for Market Data

Breaking Down McKay Brothers' Latest Maneuver Yeah, the financial market isn't just numbers and screens—it's about moving those numbers faster than a cheetah chasing prey. McKay Brothers knows this game inside and out, and they're laying down new wires, or rather, wireless, to make sure they've got the quickest routes in the room. Let me tell you, they're throwing money...

Shield HealthCare Expands Access for Astiva Members

Opening Up New Avenues for Health Care Here's a nugget from the healthcare sector that's worth chewing on. Shield HealthCare has just inked a deal with Astiva Health that opens the floodgates for eligible members in Southern California to access medical supplies through Shield's extensive network. It's a big move that aims to make health management a tad easier for folks...

Torchy's Tacos Reintroduces Nookies: Fan Favorite Returns

A Sweet Return to the Menu In the wild world of fast-casual dining, bringing back a beloved menu item is like striking gold. Torchy's Tacos is doing just that by reintroducing their legendary Nookies—fried chocolate chip cookie dough bites that have been a crowd favorite since 2008. After a two-year hiatus, these treats are back, complete with a cinnamon-sugar twist to...

CopperWood Senior Living Revives Historic Campus

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

LUNGevity's Every Breath Forward Drives Awareness and Action

A Bold New Campaign for Lung Cancer Awareness Amidst the hustle and bustle of daily life, a solemn campaign rises, taking aim at lung cancer's staggering toll on lives. LUNGevity Foundation is rolling out its initiative, Every Breath Forward?, this November, spotlighting unity and action during Lung Cancer Awareness Month. Forget the red carpets and flashy...

NIIT Expands with Bluewater: AI-Led Workforce Revolution

Big Moves in Talent Transformation There's a shakeup in the learning space, folks, and it's all about building a more AI-driven future. Today we're dissecting how NIIT Learning Systems Limited, a name that rings a bell in global managed learning, just snapped up Bluewater Learning. Not just a small fry acquisition, oh no—this one's got some meaty implications, tallying...

Bambusa Therapeutics: IPO Priced At $16, Shares On Nasdaq

How Does Bambusa Therapeutics Stack Up? Well, here we go again in the biotech bonanza, folks. Bambusa Therapeutics is stepping onto the stage with their shiny new upsized IPO, offering a whopping 10,555,555 shares at sixteen bucks a pop. That's real money, coming in at $168,888,880 in gross proceeds if everything goes according to plan. Seems like a hefty sum, but in this...

Eli Lilly Shifts Portfolio Focus, Boosts Outlook

Strong Quarter Signals Strategic Pivots Board a runaway train, folks, 'cause Eli Lilly (NYSE:LLY) is steaming ahead with third-quarter results that'll make any investor sit up and take notice. Revenue's up 39% to a hearty $24.4 billion, with Mounjaro and Zepbound doing some serious lifting. This ain't just small potatoes; it's full-on farm territory. Financial Peaks and...

Duolingo Lawsuit Looms Over Securities Allegations

Duolingo Lawsuit: A New Headache for Investors Seems like every time you blink, another tech darling is getting dragged to court, and now it's Duolingo's turn to face the music. They're locked in a class action lawsuit food-fight over violations of the Securities Exchange Act of 1934, specifically, §§10(b) and 20(a), and Rule 10b-5. The Core of Allegations Against...